Johnson & Johnson said it would begin a final 60,000-person trial of a single-shot COVID-19 vaccine, which could prove easier to administer than rivals that require two inoculations.

Subscribe: http://smarturl.it/reuterssubscribe

Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.

Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en